Stock listing
OTC:ANTH Anthera Pharmaceuticals Inc Stock
Follow Anthera Pharmaceuticals Inc into a list and get an email when it puts out news.

- Ticker
- OTC:ANTH
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
Anthera Pharmaceuticals Inc on 6ix
- Decks
- 1 deck · latest Nov 13, 2012
Valuation
- Enterprise value
- No market cap
- P/E
- No market cap
- EV/sales
- No market cap
- EV/EBITDA
- No market cap
- Price/book
- No market cap
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.00
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2024 | Nov 18, 2024 | 0.0% |
| Quarter to Jun 30, 2024 | Aug 7, 2024 | 0.0% |
| Quarter to Mar 31, 2024 | May 9, 2024 | 0.0% |
| Quarter to Dec 31, 2023 | Mar 5, 2024 | 0.0% |
| Quarter to Sep 30, 2023 | Nov 6, 2023 | 0.0% |
| Quarter to Jun 30, 2023 | Aug 9, 2023 | 0.0% |
| Quarter to Mar 31, 2023 | May 11, 2023 | 0.0% |
| Quarter to Dec 31, 2022 | Mar 7, 2023 | 0.0% |
| Quarter to Sep 30, 2022 | Nov 7, 2022 | 0.0% |
| Quarter to Jun 30, 2022 | Aug 10, 2022 | 0.0% |
All 16 quarters
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2022 | May 12, 2022 | 0.0% |
| Quarter to Dec 31, 2021 | Mar 8, 2022 | 0.0% |
| Quarter to Sep 30, 2021 | Nov 8, 2021 | 0.0% |
| Quarter to Jun 30, 2021 | Aug 11, 2021 | −8.8% |
| Quarter to Mar 31, 2021 | May 13, 2021 | +7.5% |
| Quarter to Dec 31, 2020 | Mar 9, 2021 | −20.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (November 2012) | Technical | 7 slides | Nov 13, 2012 |
Financials
Annual, in USD
Income statement
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 145.0K | 3.19M | 0 | 0 | 0 | ||||
| Cost of revenue | 281.0K | 46.3K | 30.9K | 21.8M | 21.7K | 24.2K | ||||
| Gross profit | -281.0K | 98.7K | 3.15M | -21.8M | -21.7K | -24.2K | ||||
| Research and development | 28.6M | 46.3M | 30.9M | 21.8M | 21.7M | 49.2M | ||||
| Selling, general and administrative | 7.94M | 11.1M | 7.57M | 6.62M | 6.56M | 6.71M | ||||
| Operating income | -36.4M | -57.2M | -35.2M | -28.5M | -28.2M | -55.9M | ||||
| Depreciation and amortization | 228.5K | 236.6K | 206.3K | 171.9K | 281.0K | 266.0K | 285.0K | 344.0K | 353.0K | 331.0K |
| EBITDA | -36.2M | -56.9M | -35.0M | -28.1M | -27.9M | -55.6M | ||||
| Interest expense | 0 | 0 | 0 | 1.05M | 2.60M | 3.35M | ||||
| Income before tax | -26.9M | -55.5M | -35.2M | -29.6M | -30.9M | -59.4M | ||||
| Income tax | -9.94M | -1.92M | -308.0K | 705.0K | 2.25M | 3.02M | ||||
| Net income | -16.9M | -53.6M | -34.9M | -30.3M | -33.1M | -59.4M | ||||
| Earnings per share, basic | -1.65 | -10.38 | -7.84 | -11.13 | -14.50 | -65.77 |
Balance sheet
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 2.20M | 20.8M | 47.0M | 2.64M | 25.9M | 19.4M | ||||
| Short-term investments | 0 | 0 | 0 | 0 | 0 | 5.32M | ||||
| Receivables | 326.0K | |||||||||
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Current assets | 3.19M | 22.7M | 47.9M | 3.02M | 26.3M | 24.8M | ||||
| Property, plant and equipment | 482.0K | 763.0K | 263.0K | 468.0K | 812.0K | 1.15M | ||||
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Total assets | 3.67M | 23.5M | 48.1M | 3.49M | 37.4M | 26.4M | ||||
| Accounts payable | 1.83M | 4.78M | 5.26M | 2.23M | 3.52M | 5.21M | ||||
| Current liabilities | 4.71M | 10.6M | 8.47M | 5.75M | 7.56M | 9.42M | ||||
| Long-term debt | 0 | 0 | 0 | 0 | 15.1M | 11.2M | ||||
| Total debt | 17.9M | 20.6M | ||||||||
| Total liabilities | 9.17M | 11.0M | 8.47M | 5.75M | 22.7M | 30.0M | ||||
| Shareholders' equity | -5.50M | 12.5M | 39.7M | -2.26M | 14.8M | -3.53M | ||||
| Shares outstanding | 22.2M | 22.2M | 22.2M | 22.2M | 10.3M | 5.16M | 4.45M | 2.72M | 2.28M | 903.2K |
Cash flow
| Line | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|
| Cash from operations | -36.9M | -48.9M | -30.9M | -25.6M | -31.9M | -73.6M |
| Capital spending | -919.9K | -766.0K | -80.0K | -80.0K | -15.0K | -207.0K |
| Free cash flow | -36.9M | -49.7M | -31.0M | -25.6M | -31.9M | -73.8M |
| Cash from investing | -919.9K | -766.0K | -80.0K | 10.0M | -4.69M | -3.78M |
| Cash from financing | 18.3M | 23.6M | 75.3M | -7.71M | 43.1M | 31.3M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 270.0K | 6.72M | 75.3M | 10.4M | -32 | -37 |
| Change in cash | -18.6M | -26.1M | 44.3M | -23.3M | 6.51M | -46.2M |
Cap table
Built by 6ix from Anthera Pharmaceuticals Inc’s releases
- Common shares
- 26,179,302
- Fully diluted
- 26,179,302
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 26,179,302 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 26,179,302 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christopher P Lowe Other companies: Vincerx Pharma Inc (Director · May 13, 2021 – Aug 24, 2022 · Past); Quince Therapeutics, Inc. (Interim CEO, COO & CFO · May 8, 2019 – Mar 3, 2022 · Past); Hansen Medical Inc (Interim CFO, Director · Nov 15, 2006 – Jul 27, 2016 · Past) | CFO and Chief Business Officer · Feb 23, 2010 – May 17, 2013 · Past |
| John Craig Thompson Other companies: Esperion Therapeutics, Inc. (Director · Since at least Jul 1, 2025); Tetraphase Pharmaceuticals Inc (Chief Operating Officer · Feb 3, 2014 – Sep 8, 2015 · Past); Trius Therapeutics Inc (Chief Commercial Officer · Mar 8, 2012 – Sep 11, 2013 · Past) | President & CEO, Director · Jan 7, 2016 – Jan 5, 2018 · Past |
| Annette Bianchi Other companies: Conceptus Inc (Director · Jun 7, 2006 – Jun 4, 2008 · Past) | Director · Feb 23, 2010 – Apr 19, 2011 · Past |
| A. Rachel Leheny Other companies: CalciMedica, Inc. (Chief Executive Officer · Since at least Mar 20, 2023) | Director · Feb 23, 2010 – Sep 30, 2010 · Past |
| Bogdan Dziurzynski Other companies: Dendreon Corp (Director · Jun 15, 2006 – Jan 3, 2014 · Past) | Director · Mar 1, 2012 – May 31, 2013 · Past |
| Brent Furse Other companies: The Medicines Company (EVP, Chief Customer Officer · Mar 3, 2014 – Aug 29, 2014 · Past) | Director · Apr 27, 2016 – Jan 5, 2018 · Past |
| Brian R. Mueller Other companies: BioMarin Pharmaceutical Inc. (Executive Vice President, Chief Financial Officer · Since at least Dec 31, 2011) | Director · Jun 18, 2014 – Jan 5, 2018 · Past |
| Charles V Olson Other companies: Edesa Biotech, Inc. (Director · Since at least Dec 8, 2016) | Chief Technology Officer · Jan 5, 2016 – May 20, 2017 · Past |
| James E Pennington | Chief Medical Officer & Ex. VP · Feb 23, 2010 – Feb 23, 2010 · Past |
| May Liu | Principal Accounting Officer · May 28, 2013 – Jan 5, 2018 · Past |
All 13 people
| Person | Seat |
|---|---|
| Philip Sager | Director · Jan 5, 2018 – Jan 5, 2018 · Past |
| Stephen Lau | VP, Corp. & Business Dev. · Feb 23, 2010 – Jun 30, 2010 · Past |
| Ursula Fritsch | VP, Glob. Reg. & Compliance · Feb 23, 2010 – Jun 30, 2010 · Past |
Log in to ask 6ix AI your own questions about Anthera Pharmaceuticals Inc.